Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment

New tools are needed to match cancer patients with effective treatments. Patient-derived organoids offer a high-throughput platform to personalize treatments and discover novel therapies. Currently, methods to evaluate drug response in organoids are limited because they overlook cellular heterogenei...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharick, Joe T., Walsh, Christine M., Sprackling, Carley M., Pasch, Cheri A., Pham, Dan L., Esbona, Karla, Choudhary, Alka, Garcia-Valera, Rebeca, Burkard, Mark E., McGregor, Stephanie M., Matkowskyj, Kristina A., Parikh, Alexander A., Meszoely, Ingrid M., Kelley, Mark C., Tsai, Susan, Deming, Dustin A., Skala, Melissa C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242740/
https://www.ncbi.nlm.nih.gov/pubmed/32500020
http://dx.doi.org/10.3389/fonc.2020.00553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242740/
https://www.ncbi.nlm.nih.gov/pubmed/32500020
http://dx.doi.org/10.3389/fonc.2020.00553

Ejemplares similares